
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2478289/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The role of glial cells in multiple sclerosis disease progression. Nature Reviews Neurology, 2022, 18, 237-248.	10.1	53
2	Stroke induces disease-specific myeloid cells in the brain parenchyma and pia. Nature Communications, 2022, 13, 945.	12.8	40
3	Tissue donations for multiple sclerosis research: current state and suggestions for improvement. Brain Communications, 2022, 4, fcac094.	3.3	4
4	Interleukin-4 receptor signaling modulates neuronal network activity. Journal of Experimental Medicine, 2022, 219, .	8.5	11
5	IL-24 intrinsically regulates Th17 cell pathogenicity in mice. Journal of Experimental Medicine, 2022, 219,	8.5	4
6	Beneficial contribution of induced pluripotent stem cellâ€progeny to Connexin 47 dynamics during demyelinationâ€remyelination. Glia, 2021, 69, 1094-1109.	4.9	7
7	Absence of B Cells in Brainstem and White Matter Lesions Associates With Less Severe Disease and Absence of Oligoclonal Bands in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	16
8	One-step Reprogramming of Human Fibroblasts into Oligodendrocyte-like Cells by SOX10, OLIG2, and NKX6.2. Stem Cell Reports, 2021, 16, 771-783.	4.8	19
9	<scp>SKAP2</scp> as a new regulator of oligodendroglial migration and myelin sheath formation. Glia, 2021, 69, 2699-2716.	4.9	16
10	Cover Image, Volume 69, Issue 11. Glia, 2021, 69, C1.	4.9	0
11	G-protein-coupled receptor P2Y10 facilitates chemokine-induced CD4 T cell migration through autocrine/paracrine mediators. Nature Communications, 2021, 12, 6798.	12.8	19
12	Stem cell derived oligodendrocytes to study myelin diseases. Glia, 2020, 68, 705-720.	4.9	46
13	Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS. Acta Neuropathologica Communications, 2020, 8, 207.	5.2	11
14	Multiple sclerosis iPS-derived oligodendroglia conserve their properties to functionally interact with axons and glia in vivo. Science Advances, 2020, 6, .	10.3	29
15	Lesion stage-dependent causes for impaired remyelination in MS. Acta Neuropathologica, 2020, 140, 359-375.	7.7	69
16	Extrinsic immune cell-derived, but not intrinsic oligodendroglial factors contribute to oligodendroglial differentiation block in multiple sclerosis. Acta Neuropathologica, 2020, 140, 715-736.	7.7	53
17	Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions. Brain, 2020, 143, 1714-1730.	7.6	131
18	Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nature Communications, 2020, 11, 247.	12.8	242

#	Article	IF	CITATIONS
19	TMEM10 Promotes Oligodendrocyte Differentiation and is Expressed by Oligodendrocytes in Human Remyelinating Multiple Sclerosis Plaques. Scientific Reports, 2019, 9, 3606.	3.3	27
20	The K _{2P} â€channel TASK1 affects Oligodendroglial differentiation but not myelin restoration. Glia, 2019, 67, 870-883.	4.9	7
21	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nature Communications, 2019, 10, 5779.	12.8	87
22	Association between pathological and MRI findings in multiple sclerosis. Lancet Neurology, The, 2019, 18, 198-210.	10.2	163
23	Interferon Î ² -Mediated Protective Functions of Microglia in Central Nervous System Autoimmunity. International Journal of Molecular Sciences, 2019, 20, 190.	4.1	22
24	Nfat/calcineurin signaling promotes oligodendrocyte differentiation and myelination by transcription factor network tuning. Nature Communications, 2018, 9, 899.	12.8	60
25	Single Site Fluorination of the GM ₄ Ganglioside Epitope Upregulates Oligodendrocyte Differentiation. ACS Chemical Neuroscience, 2018, 9, 1159-1165.	3.5	21
26	Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis. Nature Neuroscience, 2018, 21, 1392-1403.	14.8	64
27	ALK3 undergoes ligand-independent homodimerization and BMP-induced heterodimerization with ALK2. Free Radical Biology and Medicine, 2018, 129, 127-137.	2.9	17
28	Nur77 serves as a molecular brake of the metabolic switch during T cell activation to restrict autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8017-E8026.	7.1	93
29	Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2243-E2252.	7.1	189
30	Astrocyte pathology in a human neural stem cell model of frontotemporal dementia caused by mutant TAU protein. Scientific Reports, 2017, 7, 42991.	3.3	76
31	Activation of FXR pathway does not alter glial cell function. Journal of Neuroinflammation, 2017, 14, 66.	7.2	9
32	An updated histological classification system for multiple sclerosis lesions. Acta Neuropathologica, 2017, 133, 13-24.	7.7	436
33	Achievements and obstacles of remyelinating therapies in multiple sclerosis. Nature Reviews Neurology, 2017, 13, 742-754.	10.1	89
34	BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions. Science Translational Medicine, 2017, 9, .	12.4	138
35	Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation. PLoS ONE, 2016, 11, e0158599.	2.5	9
36	Recovery from Toxic-Induced Demyelination Does Not Require the NG2 Proteoglycan. PLoS ONE, 2016, 11, e0163841.	2.5	6

#	Article	IF	CITATIONS
37	CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. Nature Communications, 2016, 7, 11153.	12.8	98
38	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2973-82.	7.1	157
39	B7-H1 shapes T-cell–mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6182-E6191.	7.1	24
40	The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion. Acta Neuropathologica, 2016, 132, 413-431.	7.7	26
41	Long-term efficacy of alemtuzumab in polymyositis. Rheumatology, 2015, 54, 560-562.	1.9	14
42	Distinct Neurodegenerative Changes in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia Linked to Mutant TAU Protein. Stem Cell Reports, 2015, 5, 83-96.	4.8	82
43	Non-steroidal anti-inflammatory drug indometacin enhances endogenous remyelination. Acta Neuropathologica, 2015, 130, 247-261.	7.7	28
44	VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. Journal of Experimental Medicine, 2014, 211, 1833-1846.	8.5	134
45	Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination. Acta Neuropathologica Communications, 2014, 2, 168.	5.2	34
46	Puma, but not noxa is essential for oligodendroglial cell death. Glia, 2013, 61, 1712-1723.	4.9	16
47	Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian Neurodegeneration to ERK-Dependent Changes in Gene Expression. Cell Stem Cell, 2013, 12, 354-367.	11.1	448
48	Relapsing–remitting and primary progressive MS have the same cause(s)- the neuropathologist's view: 2. Multiple Sclerosis Journal, 2013, 19, 268-269.	3.0	13
49	Limited TCF7L2 Expression in MS Lesions. PLoS ONE, 2013, 8, e72822.	2.5	24
50	Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?. Acta Neuropathologica, 2012, 123, 627-638.	7.7	176
51	XIAP protects oligodendrocytes against cell death <i>in vitro</i> but has no functional role in toxic demyelination. Glia, 2012, 60, 271-280.	4.9	4
52	Late motor decline after accomplished remyelination: Impact for progressive multiple sclerosis. Annals of Neurology, 2012, 71, 227-244.	5.3	88
53	In toxic demyelination oligodendroglial cell death occurs early and is FAS independent. Neurobiology of Disease, 2010, 37, 362-369.	4.4	77
54	Nogo-A is a Reliable Oligodendroglial Marker in Adult Human and Mouse CNS and in Demyelinated Lesions. Journal of Neuropathology and Experimental Neurology, 2007, 66, 238-246.	1.7	87

#	Article	IF	CITATIONS
55	Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis. Glia, 2007, 55, 926-934.	4.9	68
56	Oligodendrocyte injury in multiple sclerosis: a role for p53. Journal of Neurochemistry, 2003, 85, 635-644.	3.9	85
57	Remyelination in multiple sclerosis. Journal of the Neurological Sciences, 2003, 206, 181-185.	0.6	175
58	Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain, 2002, 125, 2202-2212.	7.6	650
59	Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions. , 1999, 28, 34-39.		44